Development of M2BPGi: A novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics

Expert Review of Proteomics

Volumn 12, Issue 6, 2015, Pages 683-693

  Narimatsu, Hisashi ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

cirrhosis; glyco biomarker; glycoscience; hepatitis; IGOT LC MS; lectin microarray; liver fibrosis; M2BPGi; translational research; WFA positive Mac 2 binding protein

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; MAC 2 BINDING PROTEIN; UNCLASSIFIED DRUG;

CHRONIC HEPATITIS; CLINICAL STUDY; GLYCOBIOLOGY; GLYCOPROTEOMICS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; PROTEIN DETERMINATION; PROTEOMICS; REVIEW; AMINO ACID SEQUENCE; ANIMAL; BLOOD; CHEMISTRY; HEPATITIS; MOLECULAR GENETICS; PROCEDURES;

AMINO ACID SEQUENCE; ANIMALS; BIOMARKERS; GLYCOMICS; GLYCOPROTEINS; HEPATITIS; HUMANS; LIVER CIRRHOSIS; MOLECULAR SEQUENCE DATA;

EID: 84947490600     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2015.1084874     Document Type: Review

References (78)

1. Varki A. Essentials of glycobiology. 2nd edition. Cold spring harbor laboratory press, Cold spring harbor, NY; 1999
2. Cantarel BL, Coutinho PM, Rancurel C, et al. The Carbohydrate-active enzymes database (CAZy): an expert resource for Glycogenomics. Nucleic Acids Res. 2009; 37 (Database issue): D233-8
3. Carbohydrate-Active enZYmes Database. Available from: www.cazy.org/
4. Japan Consortium for Glycobiology and Glycotechnology DataBase. Available from: http://jcggdb.jp/index-en.html
5. Maeda M, Fujita N, Suzuki Y, et al. JCGGDB: Japan Consortium for Glycobiology and Glycotechnology Database. Methods Mol Biol 2015; 1273: 161-79
6. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126 (5): 855-67
7. Kobata A, Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005; 83 (4): 429-39
8. Futakawa S, Nara K, Miyajima M, et al. A unique N -glycan on human transferrin in CSF: a possible biomarker for iNPH. Neurobiol Aging 2012; 33 (8): 1807-15
9. Sun W, Grassi P, Engström A, et al. N -glycans of human protein C inhibitor: tissue-specific expression and function. PLoS One 2011; 6 (12): e29011
10. Helenius A, Aebi M. Intracellular functions of N -linked glycans. Science 2001; 291 (5512): 2364-9
11. Jenkins N, Curling EMA. Glycosylation of recombinant proteins: Problems and prospects. Enzyme Microb Technol 1994; 16 (5): 354-64
12. Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989; 73 (1): 84-9
13. Bork K, Reutter W, Weidemann W, Horstkorte R. Enhanced sialylation of EPO by overexpression of UDP-GlcNAc 2-epimerase/ManAc kinase containing a sialuria mutation in CHO cells. FEBS Lett 2007; 581 (22): 4195-8
14. Hirao Y, Matsuzaki H, Iwaki J, et al. Glycoproteomics approach for identifying Glycobiomarker candidate molecules for tissue type classification of non-small cell lung carcinoma. J Proteome Res 2014; 13 (11): 4705-16
15. Matsuda A, Kuno A, Kawamoto T, et al. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology 2010; 52 (1): 174-82
16. Onuma Y, Tateno H, Hirabayashi J, et al. rBC2LCN, a new probe for live cell imaging of human pluripotent stem cells. Biochem Biophys Res Commun 2013; 431 (3): 524-9
17. Hakomori S. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci 2002; 99 (16): 10231-3
18. Ruhaak LR, Miyamoto S, Lebrilla CB. Developments in the Identification of Glycan Biomarkers for the Detection of Cancer. Mol Cell Proteomics 2013; 12 (4): 846-55
19. Kuno A, Ikehara Y, Tanaka Y, et al. A serum sweet-doughnut protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065
20. Aoyagi Y, Isemura M, Suzuki Y, et al. Fucosylated α-f etoprotein as marker of early hepatocellular carcinoma. Lancet 1985; 326 (8468): 1353-4
21. Kobayashi M, Kuroiwa T, Suda T, et al. Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol Res 2007; 37 (11): 914-22
22. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983; 43 (11): 5489-92
23. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998; 58 (3): 512-18
24. Takeuchi H, Kato K, Denda-Nagai K, et al. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3 N -acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. J Immunol Methods 2002; 270 (2): 199-209
25. Sorensen AL, Reis CA, Tarp MA, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006; 16 (2): 96-107
26. Kjeldsen T, Clausen H, Hirohashi S, et al. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha- N -acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988; 48 (8): 2214-20
27. Yonezawa S, Kitajima S, Higashi M, et al. A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach. Gastric Cancer 2012; 15 (4): 370-81
28. Hirabayashi J, Yamada M, Kuno A, Tateno H. Lectin microarrays: concept, principle and applications. Chem Soc Rev 2013; 42 (10): 4443-58
29. Levery SB, Steentoft C, Halim A, et al. Advances in mass spectrometry driven O -glycoproteomics. Biochim Biophys Acta-Gen Subj 2015; 1850 (1): 33-42
30. Thaysen-Andersen M, Packer NH. Advances in LC-MS/MS-based glycoproteomics: Getting closer to system-wide site-specific mapping of the N- and O -glycoproteome. Biochim Biophys Acta-Proteins Proteomics 2014; 1844 (9): 1437-52
31. Narimatsu H, Sawaki H, Kuno A, et al. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010; 277 (1): 95-105
32. Kaji H, Ocho M, Togayachi A, et al. Glycoproteomic discovery of serological biomarker candidates for HCV/HBV infection-associated liver fibrosis and hepatocellular carcinoma. J Proteome Res 2013; 12 (6): 2630-40
33. Kolarich D, Lepenies B, Seeberger PH. Glycomics, glycoproteomics and the immune system. Curr Opin Chem Biol 2012; 16 (1-2): 214-20
34. Wada Y, Azadi P, Costello CE, et al. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiol 2007; 17 (4): 411-22
35. Nilsson J, Ruetschi U, Halim A, et al. Enrichment of glycopeptides for glycan structure and attachment site identification. Nat Meth 2009; 6 (11): 809-11
36. Kolli V, Schumacher KN, Dodds ED. Engaging challenges in glycoproteomics: recent advances in MS-based glycopeptide analysis. Bioanalysis 2015; 7 (1): 113-31
37. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115 (2): P209-18
38. Kuno A, Uchiyama N, Koseki-Kuno S, et al. Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2005; 2 (11): 851-6
39. Kuno A, Kato Y, Matsuda A, et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification. Mol Cell Proteomics 2009; 8 (1): 99-108
40. Kaji H, Saito H, Yamauchi Y, et al. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N -linked glycoproteins. Nat Biotech 2003; 21 (6): 667-72
41. Kaji H, Yamauchi Y, Takahashi N, Isobe T. Mass spectrometric identification of N -linked glycopeptides using lectin-mediated affinity capture and glycosylation site-specific stable isotope tagging. Nat Protoc 2007; 1 (6): 3019-27
42. Kuno A, Matsuda A, Ikehara Y, et al. Glycomics. In: Enzymology MFBT-M, Glycomics,. editor. Chapter seven-differential glycan profiling by lectin microarray targeting tissue specimens. Academic Press, 2010. p. 165-79
43. Ikehara Y, Sato T, Niwa T, et al. Apical Golgi localization of N,N-diacetyllactosediamine synthase, beta4GalNAc-T3, is responsible for LacdiNAc expression on gastric mucosa. Glycobiology 2006; 16 (9): 777-85
44. Zhang H, Li X, Martin DB, Aebersold R. Identification and quantification of N -linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotech 2003; 21 (6): 660-6
45. Sugahara D, Tomioka A, Sato T, et al. Large-scale identification of secretome glycoproteins recognized by wisteria floribunda agglutinin: a glycoproteomic approach to biomarker discovery. Proteomics 2015; 1-34
46. Sogabe M, Nozaki H, Tanaka N, et al. Novel glycobiomarker for ovarian cancer that detects clear cell carcinoma. J Proteome Res 2014; 13 (3): 1624-35
47. Ocho M, Togayachi A, Iio E, et al. Application of a glycoproteomics-based biomarker development method: alteration in glycan structure on colony stimulating factor 1 receptor as a possible glycobiomarker candidate for evaluation of liver cirrhosis. J Proteome Res 2014; 13 (3): 1428-37
48. Toshima T, Shirabe K, Ikegami T, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis. J Gastroenterol 2015; 50 (1): 76-84
49. Yamasaki K, Tateyama M, Abiru S, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60 (5): 1563-70
50. Abe M, Miyake T, Kuno A, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2014; 1-9
51. Tamaki N, Kurosaki M, Kuno A, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015. [. Epub ahead of print]
52. UniProtKB-Q08380 (LG3BP-HUMAN). Available from: www.uniprot.org/uniprot/Q08380
53. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds β1 integrins, collagens and fibronectin. EMBO J 1998; 17 (6): 1606-13
54. Iacovazzi PA, Trisolini A, Barletta D, et al. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 2001; 39 (10): 961-5
55. Kuno A, Ikehara Y, Tanaka Y, et al. LecT-Hepa: A triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine. Clin Chim Acta 2011; 412 (19-20): 1767-72
56. Ito K, Kuno A, Ikehara Y, et al. LecT-hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 2012; 56 (4): 1448-56
57. Toshima T, Shirabe K, Takeishi K, et al. New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver. J Gastroenterol 2011; 46 (5): 705-11
58. Hanai T, Shiraki M, Ohnishi S, et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res 2015. [. Epub ahead of print]
59. Lok AS. Personalized treatment of hepatitis B. Clin Mol Hepatol 2015; 21 (1): 1-6
60. Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol 2015; 62 (1 Supp): S15-24.
61. Hirabayashi J, Hayama K, Kaji H, Isobe T, Kasai K. Affinity capturing and gene assignment of soluble glycoproteins produced by the nematode Caenorhabditis elegans. J Biochem 2002; 132 (1): 103-14.
62. Iwai T, Kudo T, Kawamoto R, et al. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A 2005; 102 (12): 4572-77
63. Sato T, Sato M, Kiyohara K, et al. Molecular cloning and characterization of a novel human beta1,3-glucosyltransferase, which is localized at the endoplasmic reticulum and glucosylates O-linked fucosylglycan on thrombospondin type 1 repeat domain. Glycobiology 2006; 16 (12): 1194-1206
64. Ito H, Kameyama A, Sato T, Kiyohara K, Nakahara Y, Narimatsu H. Molecular-weight-tagged glycopeptide library: efficient construction and applications. Angew Chem Int Ed Engl 2005; 44 (29): 4547-9.
65. Ito H, Kameyama A, Sato T, Sukegawa M, Ishida H-K, Narimatsu H. Strategy for the fine characterization of glycosyltransferase specificity using isotopomer assembly. Nat Methods 2007; 4 (7): 577-82.
66. Amano K, Chiba Y, Kasahara Y, et al. Engineering of mucin-type human glycoproteins in yeast cells. Proc Natl Acad Sci U S A 2008; 105 (9): 3232-7
67. Kameyama A, Kikuchi N, Nakaya S, et al. A strategy for identification of oligosaccharide structures using observational multistage mass spectral library. Anal Chem 2005; 77 (15): 4719-25
68. Kameyama A, Nakaya S, Ito H, et al. Strategy for simulation of CID spectra of N -linked oligosaccharides toward glycomics. J Proteome Res 2006; 5 (4): 808-14
69. Ito H, Kameyama A, Sato T, Narimatsu H. Preparation of a glycan library using a variety of glycosyltrasferases. Methods Mol Biol 2009; 534: 283-91
70. Uchiyama N, Kuno A, Koseki-Kuno S, et al. Development of a lectin microarray based on an evanescent-field fluorescence principle. Methods Enzymol 2006; 415: 341-51
71. Kato Y, Kaneko MK, Kuno A, et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006; 349 (4): 1301-7
72. Ikehara Y, Niwa T, Biao L, et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res 2006; 66 (17): 8740-8
73. Ikehara N, Shiuchi N, Kabata-Ikehara S, et al. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett 2008; 260 (1-2): 137-45
74. Kikuchi N, Narimatsu H. Bioinformatics for comprehensive finding and analysis of glycosyltransferases. Biochim Biophys Acta 2006; 1760 (4): 578-83
75. Togayachi A, Kozono Y, Ishida H, et al. Polylactosamine on glycoproteins influences basal levels of lymphocyte and macrophage activation. Proc Natl Acad Sci U S A 2007; 104 (40): 15829-34
76. Togayachi A, Kozono Y, Ikehara Y, et al. Lack of lacto/neolacto-glycolipids enhances the formation of glycolipid-enriched microdomains, facilitating B cell activation. Proc Natl Acad Sci U S A 2010; 107 (26): 11900-5
77. Sato T, Kudo T, Ikehara Y, et al. Chondroitin sulfate N -acetylgalactosaminyltransferase 1 is necessary for normal endochondral ossification and aggrecan metabolism. J Biol Chem 2011; 286 (7): 5803-12
78. Ito H, Kuno A, Sawaki H, et al. Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. J Proteome Res 2009; 8 (3): 1358-67